Tag: FY24
Indegene reports revenue over INR 2,500 crores for FY24
Indegene Limited posts strong financial growth with a 12.3% increase in revenue, a 28.6% rise in EBITDA, and a 26.5% surge in profit after tax, driven by robust operations and strategic client partnerships
Fortis reports 9.5% revenue growth in FY24
Fortis sees significant growth in hospital and diagnostics businesses, recommends dividend of Rs 1 per share, and strengthens NCR presence with new 450-bed hospital acquisition
Morepen Labs reports 143% surge in profit during FY24
FY24 witnesses a 20% increase in revenue, Dr. Morepen medical devices sales skyrocket by 35% as company marks 40 years
Credit profile of Indian pharma companies to remain healthy in FY2025:...
Revenue growth to moderate to 8-10% in FY2025, post a healthy 13-14% YoY expansion in FY2024